RxDoctor Payments Data

Amy Baker, APRN

Adult Health · Paducah, KYNPI 1932532934

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $12,730 of the $14,184 with a category attached, or 89.7%. It is spread thinly across 60 manufacturers, the largest accounting for just 11.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $4,369 and has fallen 55.2% since, to $1,958 in 2025. Among adult health clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$14,184in general payments, 2019–2025

Across 578 payments — averaging $24.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$2K
  • AstraZeneca$1K
  • Novartis$1K
  • Daiichi Sankyo Inc.$839
  • Seagen Inc.$604
  • Amgen$551
  • plus $8K from 54 others

What the payments were for

  • Food & beverage$12,73090%
  • Education$8236%
  • Other$6324%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson(2 entities)55$1,672
AstraZeneca(2 entities)44$1,392
Novartis38$1,077
Daiichi Sankyo Inc.25$839
Seagen Inc.29$604
Amgen37$551
Pfizer31$537
Incyte Corporation23$505
Sanofi21$483
Merck28$438
E.r. Squibb & Sons, L.L.C.7$432
Rigel Pharmaceuticals, Inc.11$383
Regeneron Healthcare Solutions, Inc.11$325
Ipsen Biopharmaceuticals, Inc11$323
Bristol Myers Squibb22$309
Takeda Pharmaceuticals U.S.A., Inc.8$296
Lilly USA, LLC6$235
Gilead5$226
Geron Corporation3$201
Exelixis Inc.9$199
GSK9$182
Pharmaessentia USA Corporation4$178
Eisai Inc.10$176
Novo Nordisk6$167
Puma Biotechnology, Inc.6$164
Beigene USA, Inc.3$153
Karyopharm Therapeutics Inc.8$147
Tempus AI, Inc2$129
Astellas Pharma US Inc3$107
AbbVie6$106
Epizyme, Inc.7$104
EMD Serono, Inc.5$99
Pharmacyclics LLC, An Abbvie Company7$99
Taiho Oncology, Inc.7$96
Adaptive Biotechnologies Corporation4$96
Springworks Therapeutics, Inc.2$89
Boehringer Ingelheim4$71
Global Blood Therapeutics, Inc.4$66
Acceleron Pharma, Inc.4$60
Coherus Oncology, Inc.4$60
Bayer4$56
Tersera Therapeutics LLC3$55
Stemline Therapeutics Inc.2$54
Kyowa Kirin, Inc.3$54
Servier Pharmaceuticals LLC3$49
Morphosys, US Inc.3$46
ADMA Biomanufacturing LLC2$35
Alnylam Pharmaceuticals Inc.2$33
Array Biopharma Inc2$33
Pharmacosmos Therapeutics Inc.2$31
Novocure Inc.2$29
Genentech USA, Inc.2$29
Sobi, Inc1$25
Blueprint Medicines Corporation1$23
G1 Therapeutics, Inc.1$20
Iovance Biotherapeutics, Inc.1$19
Cumberland Pharmaceuticals, Inc.1$18
Jazz Pharmaceuticals Inc.1$18
Acrotech Biopharma Inc.1$18
Sumitomo Pharma America, Inc.1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,184 in reported general payments places this provider in the 95th percentile of 170 adult health providers in Kentucky.

See all adult health providers in Kentucky

Medicare billing

Part B allowed, 2024
$82,933
Medicare patients
432
Services billed
1,350

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IbrancePalbociclib41$645,490
JakafiRuxolitinib Phosphate23$379,344
BrukinsaZanubrutinib26$240,828
Lenalidomide22$234,048
EliquisApixaban102$85,331
XareltoRivaroxaban14$11,340
Tamoxifen Citrate268$6,395
Ondansetron Hcl37$5,295
Letrozole257$4,139
Anagrelide Hcl12$3,919
Enoxaparin Sodium12$3,478
Exemestane12$2,913
Alendronate Sodium161$1,420
Warfarin Sodium54$656
Potassium Chloride44$642

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerIbrance, Eliquis$537$730,822143 claims
Incyte CorporationJakafi$505$379,34423 claims
Beigene USA, Inc.Brukinsa$153$240,82826 claims
Johnson & JohnsonXarelto$1,672$11,34014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 170 adult health providers in Kentucky.

Other adult health in Paducah

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →